AC Immune SA (ACIU) vs BridgeBio Oncology Therapeutics (BBOT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AC Immune SA (ACIU) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 28.4% versus a loss of 71.8%. BridgeBio Oncology Therapeutics is the larger company by market cap ($274.2 million vs $253.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | BBOT |
|---|---|---|
| Share price | $2.55 | $3.42 |
| Market cap | $253.54M | $274.20M |
| 1-day change | -0.78% | -0.58% |
| YTD return | -18.15% | -72.52% |
| 1-year return | -28.41% | -71.83% |
| 5-year return | -58.41% | — |
| Forward P/E | 4.28 | — |
| EPS (TTM) | $-0.54 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $14.87 |
| 52-week low | $2.10 | $3.27 |
| Distance from 52-week high | -36.25% | -77.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +234.12% | +617.84% |
| Average volume | 202.76K | 468.83K |
| Shares outstanding | 99.43M | 80.17M |
| Employees | 90 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed BBOT by 43.4 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
ACIU vs BBOT FAQ
Which is bigger, AC Immune SA or BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $274.20M compared with $253.54M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or BBOT?
ACIU returned -28.41% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and BridgeBio Oncology Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.